Serum T3 Level and Duration of Minimum Maintenance Dose Therapy Predict Relapse in Methimazole-Treated Graves Disease

BACKGROUND: Methimazole (MMI) has been advocated as a preferred option for most Graves disease (GD) patients. However, long-term remission after a course of MMI treatment is achieved in only 20% to 40% of patients, depending on the duration of follow-up. OBJECTIVE: To evaluate clinical factors for p...

Descripción completa

Detalles Bibliográficos
Autores principales: Thewjitcharoen, Yotsapon, Karndumri, Krittadhee, Chatchomchuan, Waralee, Porramatikul, Sriurai, Krittiyawong, Sirinate, Wanothayaroj, Ekgaluck, Butadej, Siriwan, Nakasatien, Soontaree, Rajatanavin, Rajata, Himathongkam, Thep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Clinical Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7716657/
https://www.ncbi.nlm.nih.gov/pubmed/33305160
http://dx.doi.org/10.1210/jendso/bvaa170

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7716657/
https://www.ncbi.nlm.nih.gov/pubmed/33305160
http://dx.doi.org/10.1210/jendso/bvaa170

Ejemplares similares